Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

Al‐Saleh, Yousef; Sabico, Shaun; Al-Furqani, Ahmed; Jayyousi, Amin; Alromaihi, Dalal; Ba-Essa, Ebtesam; Alawadi, Fatheya; Al-Kaabi, Juma M.; Hassanein, Mohamed; Alsifri, Saud; Saleh, Seham; Alessa, Thamer; Al-Daghri, Nasser M.

doi:10.1007/s13300-021-01059-1

Cited by 6 publications

(2 citation statements)

References 86 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A consensus document which addresses the use of – and confirms the efficacy and safety of – newer-generation SUs was developed by experts in T2D management from the Gulf Cooperation Council (GCC) countries [ 42 ]. Unlike the ADA/EASD consensus, the GCC consensus was developed following an advisory board and extensive literature reviews and surveys within the Gulf region.…”

Section: Establishing Early Glycaemic Control In Patients With Diabetesmentioning

confidence: 99%

“…Topics included epidemiology, long-term SU efficacy and safety, as well as information specific to Ramadan and weight gain. This consensus was endorsed by the Gulf Association of Endocrinology and Diabetes, the Bahrain Diabetes Society, the Emirates Diabetes and Endocrine Society, and the Saudi Scientific Diabetes Society and was informed by studies assessing the risks of hypoglycaemia, cardiovascular safety and renal benefits of the later-generation SU, gliclazide modified release (MR) [ 42 ].…”

Section: Establishing Early Glycaemic Control In Patients With Diabetesmentioning

confidence: 99%

See 1 more Smart Citation

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a leading cause of death globally, driven by the high rates of risk factors, such as diabetes and hypertension. As the prevalence of these risk factors is particularly high in the Gulf region, better diagnosis and management of type 2 diabetes (T2D) and hypertension has the potential to dramatically reduce adverse cardiovascular outcomes for individuals in that part of the world. This article provides a summary of presentations made during the EVIDENT summit, a virtual symposium on Evidence in Diabetes and Hypertension, held in September 2021, including a review of the various guidelines for both T2D and hypertension, as well as recent findings relevant to the safety and efficacy for therapies relating to these conditions. Of relevance to the Gulf region, the risk of hypoglycaemia with sulfonylureas during Ramadan was reviewed. For the management of T2D, sulfonylureas have been a long-standing medication used to achieve glycaemic control; however, differences have emerged between early and later generations, with recent studies suggesting improvements in the safety profiles of late-generation sulfonylureas. For patients with hypertension, incremental therapy changes are recommended to reduce the risk of cardiovascular complications that are associated with increasing blood pressure. For first-line therapy, angiotensin-converting enzyme inhibitors (ACEi), such as perindopril, have been demonstrated to reduce the risk of cardiovascular and all-cause mortality. The addition of calcium channel blockers and diuretics to ACEi has been shown to be effective in patients with poorly controlled hypertension. The different renin–angiotensin–aldosterone system inhibitors are reviewed, and the benefit of combination therapies, including amlodipine and indapamide in patients with difficult-to-control hypertension, is investigated. The benefits of lifestyle modifications for these patients are also discussed, with important clinical considerations that are expected to inform patient management in daily clinical practice.

show abstract

Section: Establishing Early Glycaemic Control In Patients With Diabetesmentioning

confidence: 99%

Section: Establishing Early Glycaemic Control In Patients With Diabetesmentioning

confidence: 99%

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Al Saleh,

Al Busaidi,

Al Dahi

et al. 2023

Adv Ther

View full text Add to dashboard Cite

Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review

Sahin,

Bakiner,

Demir

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and treatment; as well as the substantial impact of disease on longevity and quality of life, is a major concern in healthcare worldwide. Sulfonylureas (SUs) have been a cornerstone of T2D pharmacotherapy for over 60 years as oral antidiabetic drugs (OADs), while the newer generation SUs, such as gliclazide modified release (MR), are known to be associated with low risk of hypoglycemia in addition to the cardiovascular neutrality. This scoping review aimed to specifically address the current position of gliclazide MR among other SUs in the contemporary treatment paradigm for T2D and to provide a practical guidance document to assist clinicians in using gliclazide MR in real-life clinical practice. The main topics addressed in this paper include the role of early and sustained glycemic control and use of SUs in T2D management, the properties of gliclazide MR in relation to its effectiveness and safety, the use of gliclazide therapy in special populations, and the place of SUs as a class and gliclazide MR specifically in the current T2D treatment algorithm.

show abstract

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

Cited by 6 publications

References 86 publications

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review

Contact Info

Product

Resources

About